ArticleInternational journal of clinical and experimental medicine2015
Levels of interleukin-16 in peripheral blood of 52 patients with multiple myeloma and its clinical significance.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor.Scientific reports · 2024Article
- Fabrication of a three-dimensional bone marrow niche-like acute myeloid Leukemia disease model by an automated and controlled process using a robotic multicellular bioprinting system.Biomaterials research · 2023Article
- Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue.Oncology letters · 2018Article
- Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.Mediators of inflammation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the role of serum interleukin-16 (IL-16) in the occurrence of multiple myeloma (MM) and after the success chemotherapy and its clinical significance.
methods52 cases of MM patients, 30 cases of AML patients and 30 healthy volunteers from Jan. 2011 to Jan. 2015 were collected in this study. There was 39 MM patients received chemotherapy. Among those, 24 patients received VAD regimen chemotherapy and 15 patients received BD regimen chemotherapy. Serum IL-16, cystatin C (Cys-C), lactate dehydrogenase (LDH) and levels of β2-microglobulin (β2-MG) were detected before and after the therapy of MM patients. And those results were compared to that of patients with acute myelogenous leukemia (AML) and normal people respectively.
resultsThe levels of serum IL-16, Cys-C, LDH and β2-MG in MM group were remarkably higher than that of normal control. It was of statistical significance of this difference (P<0.05). Levels of serum IL-16, Cys-C and LDH of MM patients who received therapy were all lower than that of patients before therapy. The serum IL-16 and β2-MG of 52 patients by preliminary diagnosis were analyzed through Pearson correlation analysis before they received therapy. The results showed that there was positive correlation between levels of IL-16 and β2-MG (r=0.782, P<0.01).
conclusionsA high serum IL-16 level detected in newly diagnosed MM patients and its correlation with known factors of disease activity as well as the decrease of IL-16 after chemotherapy suggest that IL-16 may be implicated and a potential therapeutic target for MM.
Indexed as
Identifiers
26885237PMC4730023W2427498331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.